As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.
Treatments for Plaque Psoriasis
Newer medications have revolutionized psoriasis care in patients with moderate-to-severe cases, says a leading dermatologist, and more drugs in the pipeline promise to offer even more choices.
Researchers have uncovered new information about the pathogenetic similarities and differences between cutaneous psoriasis and psoriatic arthritis in a recent study. They hope the information, one day, leads to a test to help doctors determine which psoriasis patients will advance with psoriatic disease.
Indigo naturalis is an Old-World plant with multiple uses. Used in China for centuries as a traditional medicine, current clinical studies are proving its effectiveness as well as identifying mechanisms of action.
Dermatologists could be making greater use of topical retinoids and vitamin D preparations in treating a variety of hyperproliferative and other skin disorders. In the early days of psoriasis treatment, the “sandwich theory” focused on epidermal turnover and inflammation, with one drug or strategy for each layer.
Although many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.
Secukinumab has received FDA approval as a new treatment option in psoriasis. A panel of experts tackles this drug’s uses, benefits, and drawbacks.
Researchers analyzed emerging oral drugs for psoriasis and concluded “… the development of new oral treatments for moderate-to-severe psoriasis has not kept pace with biologic therapies.
New Study suggests dermatologists completing a PI CME on psoriasis significantly improved in important patient care aspects. Learn more.
Can targeting differentially regulated proteins reverse or prevent disease?